In our cost-effectiveness evaluations for the National Health Authority, we have noted early human trials for AI-designed drugs in areas like oncology and fibrosis. 'AI-designed' truly means algorithms proposing molecular structures that might bind to a disease target, but the real cost lies in the subsequent years of traditional trials. My life with the electricity board taught me that a new billing system, however clever, is only as good as its implementation and upkeep—similarly, a drug's label matters less than its proven safety and final price for the janata. Does a costly, flashy solution always light up every home, beta?
#chess#world-championship
Jump in to reply — no account needed.